Collen Masimirembwa is a biochemical pharmacologist with a DPhil in Biochemistry from the University of Zimbabwe and a PhD in Pharmacogenetics from Karolinska Institute in Sweden. After working for AstraZeneca Pharmaceutical company in Sweden for 10 years as a Principal Scientist, he returned to Zimbabwe to establish the African Institute of Biomedical Science and Technology (AiBST) with the aim of promoting the sciences and technologies of drug discovery and development in Africa. He is the current President and Chief Scientific Officer of AiBST. Collen is an Honorary Professor of Clinical Pharmacology at the University of Cape Town and of Heath Sciences at the University of KwaZulu Natal. His research focus is in drug metabolism & pharmacokinetics (DMPK) and in pharmacogenomics, fields in which he has made many original contributions with over 90 research publications to his credit. Collen has won many awards in recognition of his work including a certificate of distinction in Biochemistry from the Government of Zimbabwe. Under his leadership AiBST has gained international reputation including nomination as a Centre of Excellence in DMPK & Toxicology by the African Network for Drugs and Diagnostics Innovation (ANDi). Collen is a fellow of the Zimbabwe Academy of Sciences (ZAS) and of the African Academy of Sciences (AAS).